--- title: "Bon Natural Life's interim results reflect 1-for-25 share consolidation" url: "https://aibio.space/news/bon-natural-lifes-interim-results-reflect-1-25-share-consolidation/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-09-29" section: "Listings" tickers: "NASDAQ:BON" source: "https://www.sec.gov/Archives/edgar/data/1816815/000149315225015913/ex99-1.htm" summary: "Bon Natural Life's unaudited interim statements for the six months to March 31, 2025, filed in a Form 6-K on September 29, 2025, reflect a 1-for-25 share c" --- By the aibio.space news desk. Sources - [Bon Natural Life Limited 6-K (2025-09-29)](https://www.sec.gov/Archives/edgar/data/1816815/000149315225015913/ex99-1.htm) - [Bon Natural Life Limited 20-F (2025-01-28): business](https://www.sec.gov/Archives/edgar/data/1816815/000149315225003851/form20-f.htm) [BON](https://aibio.space/companies/bon-natural-life/) 2025-09-29 # Bon Natural Life's interim results reflect 1-for-25 share consolidation and offering Tickers [BON](https://aibio.space/companies/bon-natural-life/) Bon Natural Life's unaudited interim statements for the six months to March 31, 2025, filed in a Form 6-K on September 29, 2025, reflect a 1-for-25 share consolidation and net proceeds of $10,543,805 from a public offering of Class A ordinary shares. Cash rose from $80,466 to $8,894,053 over the period. ## Key facts - **Company**: Bon Natural Life Limited (NASDAQ: BON) - **News type**: Listings - **Primary source**: [Bon Natural Life Limited 6-K (2025-09-29)](https://www.sec.gov/Archives/edgar/data/1816815/000149315225015913/ex99-1.htm) *The Washington Monument and the city beyond. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* ## The interim results Bon Natural Life Limited (Nasdaq: [BON](https://aibio.space/companies/bon-natural-life/)) furnished unaudited condensed consolidated statements for the six months ended March 31, 2025 on Form 6-K dated September 29, 2025. Revenue for the period was $7,949,845, down from $10,183,553 a year earlier. Gross profit fell to $1,907,848 from $2,968,437. Income from operations rose to $284,050 from $84,505, because operating expenses fell, with research and development costs dropping to $96,472 from $890,384. The company reported net income attributable to its shareholders of $169,227, against a loss of $10,519 a year earlier. Basic earnings per share were $0.56, against a loss of $0.20, and diluted earnings per share were $0.50. The share counts are restated for a 1-for-25 consolidation approved by shareholders at an extraordinary general meeting on April 15, 2025 and effective May 19, 2025. The profit is thin and came with a cash drain from operations. The statements show net cash used in operating activities of $4,295,567 for the six months, against $1,884,173 a year earlier, and the line for the long-term other receivable alone absorbed $14,500,947. The profit also comes against a currency loss. The foreign currency translation adjustment for the six months was a loss of $1,419,950, which turned total comprehensive income into a loss of $1,284,039. ## The offering and the cash The equity statement records the issue of 3,590,528 Class A ordinary shares for a public offering, with net proceeds of $10,543,805. The cash flow statement shows the same $10,543,805 as net proceeds from issuance of ordinary shares. The offering is the main reason cash rose, from $80,466 at September 30, 2024 to $8,894,053 at March 31, 2025. Borrowing also funded the period. The company received $7,232,644 from short-term loans and repaid $5,276,345. Short-term loans stood at $7,586,798 at March 31, 2025, up from $5,719,493 at September 30, 2024. The equity statement also records the issue of 2,041,839 Class B ordinary shares, with a reduction of 81,674 Class A shares. The statements do not explain that movement. The company now reports both Class A and Class B ordinary shares outstanding, with 3,675,677 Class A and 2,041,839 Class B shares at March 31, 2025. Total shareholders' equity rose to $53,905,305 from $44,349,539. Total assets were $71,584,129 at March 31, 2025, against $61,765,432 six months earlier. Total liabilities were $17,678,824, against $17,415,893. The balance sheet also shows a long-term other receivable of $14,449,247, which was nil at September 30, 2024. The statements do not say what the receivable is or when it is due. ## What the statements leave open The filing does not explain the long-term receivable, the Class B issue or the reduction in Class A shares. It also does not name the underwriters or any counsel for the offering, and it gives no offering price per share in the statements. The 6-K does not state whether the company expects further offerings or borrowings to cover its operations. The balance sheet also shows no assets held for sale at March 31, 2025, where it carried assets and liabilities held for sale tied to the sale of the Gansu subsidiary six months earlier. The company's annual report on Form 20-F describes a Cayman Islands holding company that operates through Hong Kong and Chinese subsidiaries. It says the company does not expect to pay cash dividends, and that its Chinese subsidiaries must set aside 10% of after-tax profits each year, if any, into statutory reserves until those reserves reach half of registered capital. The reserves are not distributable as cash dividends. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story BON Bon Natural Life Limited NASDAQ ยท China Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/bon-natural-lifes-interim-results-reflect-1-25-share-consolidation/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Bon Natural Life's interim results reflect 1-for-25 share consolidation", 2025-09-29, https://aibio.space/news/bon-natural-lifes-interim-results-reflect-1-25-share-consolidation/